Evogene (Israel) Top Management

EVGN Stock  ILA 583.60  16.20  2.70%   
Evogene employs about 133 people. The company is managed by 25 executives with a total tenure of roughly 173 years, averaging almost 6.0 years of service per executive, having 5.32 employees per reported executive. Analysis of Evogene's management performance can provide insight into the company performance.
Ofer Haviv  CEO
President, Chief Executive Officer
Martin Gerstel  Chairman
Chairman of the Board
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.

Evogene Management Team Effectiveness

The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.

Evogene Workforce Comparison

Evogene is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 812. Evogene retains roughly 133 in number of employees claiming about 16% of equities under Health Care industry.

Evogene Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Evogene Price Series Summation is a cross summation of Evogene price series and its benchmark/peer.

Evogene Notable Stakeholders

An Evogene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evogene often face trade-offs trying to please all of them. Evogene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evogene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ofer HavivPresident, Chief Executive OfficerProfile
Martin GerstelChairman of the BoardProfile
Mark KapelExecutive Vice President-TechnologyProfile
Eran KosoverExecutive Vice President & General Manager Ag-ChemicalsProfile
Ido DorExecutive Vice President & General Manager Ag-BiologicalsProfile
Alin SelaBrownVice President Screening & Validation SystemsProfile
Eyal EmmanuelExecutive Vice President-R&DProfile
Arnon HeymanVice President & General Manager of Ag-SeedsProfile
Alex TaskarChief Financial OfficerProfile
Hagai KarchiChief Technology Officer & Head of R&D Ag-BiologicalsProfile
Oded ShoseyovDirectorProfile
Adina MakoverIndependent DirectorProfile
Adrian PercyDirectorProfile
Sarit FironIndependent DirectorProfile
Leon RecanatiIndependent DirectorProfile
Kinneret SavitskyIndependent DirectorProfile
Ziv KopIndependent DirectorProfile
Yaron EldadChief OfficerProfile
Eyal RonenExec DevelProfile
Sassi MasliahExec DevelProfile
Liat WejgmanVP HRProfile
Ofer CPACEO PresProfile
Dotan BorensteinChief LtdProfile
Nir ArbelChief OfficerProfile
Elran MBAChief LtdProfile

About Evogene Management Performance

The success or failure of an entity such as Evogene often depends on how effective the management is. Evogene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evogene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evogene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.
Please note, the presentation of Evogene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Evogene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Evogene's management manipulating its earnings.

Evogene Workforce Analysis

Traditionally, organizations such as Evogene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evogene within its industry.

Evogene Manpower Efficiency

Return on Evogene Manpower

Revenue Per Employee7K
Revenue Per Executive37.2K
Net Loss Per Employee209K
Net Loss Per Executive1.1M
Working Capital Per Employee669.2K
Working Capital Per Executive3.6M

Complementary Tools for Evogene Stock analysis

When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum